Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results

Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid volume year-over-year increase of 11% and 13%Q4 and FY Thyroid revenue year-over-year increase of 14% and 21% PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the fourth quarter a ...